Vanguard Group Inc. Reduces Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Vanguard Group Inc. decreased its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,958,957 shares of the company's stock after selling 128,255 shares during the period. Vanguard Group Inc. owned approximately 4.21% of Kiniksa Pharmaceuticals worth $51,397,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. grew its position in Kiniksa Pharmaceuticals by 2.6% during the third quarter. BlackRock Inc. now owns 3,628,460 shares of the company's stock valued at $46,589,000 after buying an additional 93,103 shares during the period. State Street Corp grew its position in Kiniksa Pharmaceuticals by 20.6% during the first quarter. State Street Corp now owns 1,797,444 shares of the company's stock valued at $19,340,000 after buying an additional 307,333 shares during the period. Morgan Stanley grew its position in Kiniksa Pharmaceuticals by 14.0% during the third quarter. Morgan Stanley now owns 1,491,489 shares of the company's stock valued at $25,907,000 after buying an additional 182,746 shares during the period. Goldman Sachs Group Inc. grew its position in Kiniksa Pharmaceuticals by 61.7% during the first quarter. Goldman Sachs Group Inc. now owns 936,604 shares of the company's stock valued at $9,310,000 after buying an additional 357,387 shares during the period. Finally, ArrowMark Colorado Holdings LLC grew its position in Kiniksa Pharmaceuticals by 23.7% during the first quarter. ArrowMark Colorado Holdings LLC now owns 886,870 shares of the company's stock valued at $9,543,000 after buying an additional 169,699 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on KNSA. Wedbush reiterated an "outperform" rating and set a $30.00 target price (up previously from $28.00) on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, April 2nd. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Price Performance

NASDAQ:KNSA traded up $0.05 on Tuesday, reaching $17.73. 342,701 shares of the company's stock were exchanged, compared to its average volume of 407,341. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 98.51 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $10.29 and a 52 week high of $22.09. The stock has a fifty day simple moving average of $19.68 and a 200-day simple moving average of $17.96.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.15. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The company had revenue of $83.40 million during the quarter, compared to analyst estimates of $72.31 million. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.06 EPS for the current year.

Insider Activity

In other news, CEO Sanj K. Patel sold 12,742 shares of the firm's stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares in the company, valued at $1,517,065.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Sanj K. Patel sold 12,742 shares of the firm's stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares in the company, valued at $1,517,065.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sanj K. Patel sold 5,582 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $21.00, for a total transaction of $117,222.00. Following the completion of the sale, the chief executive officer now directly owns 65,012 shares in the company, valued at $1,365,252. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,109 shares of company stock worth $709,929. 54.23% of the stock is owned by company insiders.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.